Show simple item record

dc.contributor.authorDesar, IMEen_US
dc.contributor.authorFleuren, EDGen_US
dc.contributor.authorvan der Graaf, WTAen_US
dc.coverage.spatialUnited Statesen_US
dc.date.accessioned2019-02-27T10:04:12Z
dc.date.issued2018-03-07en_US
dc.identifierhttps://www.ncbi.nlm.nih.gov/pubmed/29516254en_US
dc.identifier10.1007/s11864-018-0525-1en_US
dc.identifier.citationCurr Treat Options Oncol, 2018, 19 (2), pp. 13 - ?en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/3103
dc.identifier.eissn1534-6277en_US
dc.identifier.doi10.1007/s11864-018-0525-1en_US
dc.description.abstractOPINION STATEMENT: Synovial sarcoma (SS) is a rare, yet highly malignant, type of soft tissue sarcoma (STS), for which survival has not improved significantly during the past years. In this review, we focus on systemic treatment in adults. Compared to other STS, SS are relatively chemosensitive. Ifosfamide and ifosfamide combinations are active in different lines of treatment. In high-risk extremity and chest wall STS, neoadjuvant doxorubicin and ifosfamide has shown as much activity as high-dose ifosfamide. There are indications that combination chemotherapy with doxorubicin and ifosfamide in this setting improves outcome. In the first-line metastatic setting, combination treatment with doxorubicin and ifosfamide is a preferred option in fit patients, while in other patients, sequential doxorubicin and ifosfamide can be considered. In second and later lines, pazopanib and trabectedin have shown activity. Many new approaches to treat metastatic SS are currently under investigation, both preclinical as well as clinical, including other receptor tyrosine kinase inhibitors, epigenetic modulators, compounds interfering with DNA damage response (DDR), and immunotherapy.en_US
dc.format.extent13 - ?en_US
dc.languageengen_US
dc.language.isoengen_US
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en_US
dc.subjectChemotherapyen_US
dc.subjectImmunotherapyen_US
dc.subjectSynovial sarcomaen_US
dc.subjectTargeted therapyen_US
dc.subjectAdulten_US
dc.subjectAntineoplastic Agentsen_US
dc.subjectAntineoplastic Combined Chemotherapy Protocolsen_US
dc.subjectDoxorubicinen_US
dc.subjectHumansen_US
dc.subjectIfosfamideen_US
dc.subjectPyrimidinesen_US
dc.subjectSarcoma, Synovialen_US
dc.subjectSulfonamidesen_US
dc.subjectTrabectedinen_US
dc.titleSystemic Treatment for Adults with Synovial Sarcoma.en_US
dc.typeJournal Article
rioxxterms.versionofrecord10.1007/s11864-018-0525-1en_US
rioxxterms.licenseref.startdate2018-03-07en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfCurr Treat Options Oncolen_US
pubs.issue2en_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical and Translational Sarcoma
pubs.publication-statusPublished onlineen_US
pubs.volume19en_US
pubs.embargo.termsNot knownen_US
icr.researchteamClinical and Translational Sarcomaen_US
dc.contributor.icrauthorvan der Graaf, Wilhelminaen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

http://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/